GSE139987 1 V 2 ROSIGLITAZONE MOUSE UP (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE139987 1 V 2 ROSIGLITAZONE MOUSE UP.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE139987 1 V 2 ROSIGLITAZONE MOUSE UP.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE139987 1 V 2 ROSIGLITAZONE MOUSE UP.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE139987 1 V 2 ROSIGLITAZONE MOUSE UP.

Results found

Linked to

 

Label

Description

 

Gene

SRC kinase signaling inhibitor 1

Gene

PHD finger protein 12

Gene

solute carrier family 25 member 25

Gene

WNK lysine deficient protein kinase 4

Gene

Ras association domain family member 8

Gene

heterogeneous nuclear ribonucleoprotein L like

Gene

B cell receptor associated protein 29

Gene

ATPase H+ transporting V0 subunit d2

Gene

synaptogyrin 1

Gene

MFSD2 lysolipid transporter B, sphingolipid

  • Gene

    SRC kinase signaling inhibitor 1


  • Gene

    PHD finger protein 12


  • Gene

    solute carrier family 25 member 25


  • Gene

    WNK lysine deficient protein kinase 4


  • Gene

    Ras association domain family member 8


  • Gene

    heterogeneous nuclear ribonucleoprotein L like


  • Gene

    B cell receptor associated protein 29


  • Gene

    ATPase H+ transporting V0 subunit d2



  • Gene

    MFSD2 lysolipid transporter B, sphingolipid

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.